COLL Collegium Pharmaceutical Inc.

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in the following investor conferences:

Jefferies London Healthcare Conference

Fireside Chat Date and Time: Tuesday, November 19, 2024, at 1:30 p.m. GMT

Piper Sandler 36th Annual Healthcare Conference

Fireside Chat Date and Time: Thursday, December 5, 2024, at 1:00 p.m. ET

The fireside chats will be webcast live and can be accessed from the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Collegium Pharmaceutical, Inc.

Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at .

Investor Contact:

Danielle Jesse

Director, Investor Relations

Media Contact:

Marissa Samuels

Vice President, Corporate Communications



                                                        





EN
12/11/2024

Underlying

COLLCollegium Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor conferences: Leerink Partners 2025 Global Healthcare ConferenceTuesday, March 11, 2025 Jefferies Biotech on the Beach SummitWednesday, March 12, 2025 Barclays 27th Annual Global Healthcare ConferenceThursday, March 13, 2025 About Collegium Pharmaceutical, Inc.Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of p...

8h / 36m 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial R...

Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results – Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported Quarterly Jornay PM® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue of $100.7 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $12.5 Million and $69.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $107.7 Million and $401.2 Million – – Ended 2024 with Cash, Cash Equivalents and Marketable Securities of $162.8 Million;...

February 27, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Result...

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025 STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2024 financial results after the market closes on Thursday, February 27, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q4 ...

February 13, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Appoints Nancy S. Lurker to its Board of Directors

Collegium Appoints Nancy S. Lurker to its Board of Directors STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. “Collegium is pleased to welcome Nancy to our Board of Directors,” said Mike Heffernan, Founder and Chairman of the Board of Collegium. “Nancy’s expertise in driving commercial growth and strategic acquisitions will be of great value to Collegium as we continue to build a leading, diversified biopharmaceutical company committed...

February 5, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Provides 2025 Financial Guidance and Business Update

Collegium Provides 2025 Financial Guidance and Business Update – Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million – – Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million – STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update. “In 2024, we executed on our prio...

January 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch